Enlivex Therapeutics Ltd.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Enlivex Therapeutics Ltd. (Nasdaq: ENLV; TASE: ENLV), an Israel-based clinical-stage macrophage reprogramming immunotherapy company founded in 2014 and headquartered in Nes-Ziona, develops and commercializes Allocetra, a proprietary off-the-shelf cell therapy platform that harnesses macrophages to treat inflammatory diseases through rebalancing immune hyper-responses; the lead product candidate Allocetra-OTS targets acute and chronic conditions including moderate knee osteoarthritis via local knee injection in the ongoing Phase III ENX-CL-05-001 trial, temporomandibular joint osteoarthritis via local TMJ injection in the investigator-initiated 1400-24-SMC study, and organ failure associated with sepsis via systemic intravenous infusion in the Phase II ENX-CL-02-002 dose-finding trial, with over 250 patients safely treated to date and no drug-related serious adverse events reported. Enlivex operates primarily in the biopharmaceutical sector, focusing on large unmet needs in musculoskeletal disorders affecting over 300 million individuals worldwide and sepsis-related organ failure, with clinical programs advancing in Israel and globally. In November 2025, the company closes a landmark $212 million private placement of ordinary shares priced at $1.00 each, marking the first public company adoption of a RAIN prediction markets token digital asset treasury strategy as its primary reserve asset to provide investor exposure to decentralized prediction protocols on the Arbitrum network; this follows a smaller $9.5 million funding in late November 2025 and coincides with the appointment of Matteo Renzi, former Prime Minister of Italy, to its Board of Directors, while maintaining focus on late-stage Allocetra development for osteoarthritis amid a market projected to impact 78 million Americans by 2040.
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity
Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis